NCT02337491View on ClinicalTrials.gov

Pembrolizumab +/- Bevacizumab for Recurrent GBM

PHASE2CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

February 9, 2015

Primary Completion Date

August 28, 2016

Study Completion Date

September 14, 2020

Conditions
Glioblastoma
Interventions
DRUG

Pembrolizumab

DRUG

Bevacizumab

Trial Locations (8)

10021

Memorial Sloan-Kettering Cancer, New York

27710

Duke University Medical Center, Durham

77030

UT, MD Anderson Cancer Center, Houston

84112

Huntsman Cancer Institute, Salt Lake City

90095

University of California, Los Angeles, Los Angeles

94143-0372

University of California, San Francisco, San Francisco

02113

Massachusetts General Hospital, Boston

02215

Dana-Farber Cancer Institute, Boston

All Listed Sponsors
lead

Dana-Farber Cancer Institute

OTHER

NCT02337491 - Pembrolizumab +/- Bevacizumab for Recurrent GBM | Biotech Hunter | Biotech Hunter